List view / Grid view
13 January 2014 | By Merck
“We’re taking significant and decisive action to make Merck a more competitive company, better positioned to drive innovation and growth...”
13 January 2014 | By GlaxoSmithKline
This transfer of rights represents the termination of the collaboration agreement between GSK and Prosensa executed in 2009....
13 January 2014 | By Teva Pharmaceuticals Industries Ltd
Multiple genes associated with potential therapeutic effects expressed differently: Gene expression analysis provides insight into variability...
13 January 2014 | By Sanofi
Genzyme will have significant rights to Alnylam’s portfolio of clinical and pre-clinical stage drug candidates...
13 January 2014 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced the FDA approved FARXIGA™ (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus...
12 January 2014 | By Novartis
Novartis announced that Hervé Hoppenot, President of Novartis Oncology, will leave Novartis with immediate effect...
The British Generic Manufacturers Association (BGMA) has appointed Thomas Broeer, managing director of Kent Pharmaceuticals, as its new chair for the next two years.
9 January 2014 | By Biogen Idec
“Our collaboration with Sangamo is expected to help us expand our capabilities to develop treatments for people with serious, inherited hematologic conditions..."
9 January 2014 | By Teva
“I would like to welcome Erez to his new position as the CEO of Teva..."
9 January 2014 | By Allergan
New aesthetic indication for market-leading neuromodulator which can now help improve appearance of lines around the eyes, as well as treating glabellar frown lines...
9 January 2014 | By Daiichi Sankyo
Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism...
8 January 2014 | By Daiichi Sankyo
Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets...
8 January 2014 | By Merck
ISENTRESS is now indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in patients four weeks of age and older...
8 January 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb application supports use of daclatasvir in combination with other agents for treating HCV patients with genotypes 1, 2, 3 and 4...
8 January 2014 | By AstraZeneca
Both companies will research and develop novel cancer therapies using Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology...
